Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination

Rivera, F. J., de la Fuente, A. G., Zhao, C., Silva, M. E., Gonzalez, G. A., Wodnar, R., Feichtner, M., Lange, S., Errea, O., Priglinger, E., O'Sullivan, A., Romanelli, P., Jadasz, J. J., Brachtl, G., Greil, R., Tempfer, H., Traweger, A., Bátiz, L. F., Küry, P., ... Aigner, L. (2019). Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination. Glia, 67(8), 1510-1525. https://doi.org/10.1002/glia.23624

Published in:
Glia

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2019 The Authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination

Francisco J. Rivera1,2,3,4,5 | Alerie G. de la Fuente5 | Chao Zhao5 | Maria E. Silva1,2,3,4,5,6 | Ginez A. Gonzalez5 | Roman Wodnar3,4 | Martina Feichtner3,4 | Simona Lange3,4 | Oihana Errea5 | Eleni Priglinger3,7,8 | Anna O'Sullivan3,4,9 | Pasquale Romanelli4,9 | Janusz J. Jadasz10 | Gabriele Bracht11,12 | Richard Greil11 | Herbert Tempfer4,8,13 | Andreas Traweger4,8,13 | Luis F. Bátiz2,14 | Patrick Küry15 | Sebastien Couillard-Despres4,8,9 | Robin J. M. Franklin5 | Ludwig Aigner3,4,8

1Laboratory of Stem Cells and Neuroregeneration, Institute of Anatomy, Histology and Pathology, Faculty of Medicine, Universidad Austral de Chile, Valdivia, Chile
2Center for Interdisciplinary Studies on the Nervous System (CISNe), Universidad Austral de Chile, Valdivia, Chile
3Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria
4Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria
5Wellcome-MRC Cambridge Stem Cell Institute & Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
6Institute of Pharmacy, Faculty of Sciences, Universidad Austral de Chile, Valdivia, Chile
7Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Linz/Vienna, Austria
8Austrian Cluster for Tissue Regeneration, Vienna, Austria
9Institute of Experimental Neuroregeneration, Paracelsus Medical University Salzburg, Salzburg, Austria
10Laboratory of Experimental Ophthalmology, Department of Ophthalmology, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany
11Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department for Hematology, Medical Oncology, Hemostasiology, Infectious Diseases, and Rheumatology, Federal Hospital of Salzburg and Paracelsus Medical University, Salzburg, Austria
12Experiment and Clinical Cell Therapy Institute, Paracelsus Medical University, Salzburg, Austria
13Institute of Tendon and Bone Regeneration, Paracelsus Medical University, Salzburg, Austria
14Centro de Investigación Biomédica (CIB), Facultad de Medicina, Universidad de los Andes, Santiago, Chile
15Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany

Abstract

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that leads to severe neurological deficits. Due to their immunomodulatory and neuroprotective properties and their ability to promote the generation of oligodendrocytes, mesenchymal stem cells (MSCs) are currently being developed for autologous cell therapy in MS. As aging reduces the regenerative capacity of all tissues, it is of relevance to investigate whether MSCs retain their pro-oligodendrogenic activity with increasing age. We demonstrate that MSCs derived from aged rats have a reduced capacity to induce
1 | INTRODUCTION

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS), commonly with onset in young adulthood and progression throughout life (Reich, Lucchinetti, & Calabresi, 2018). Therefore, the prevalence of MS is high in the aging population. In response to demyelination, CNS-resident oligodendrocyte progenitor cells (OPCs) become activated, proliferate, and migrate to the lesion and differentiate into new oligodendrocytes, completing remyelination (Franklin & Ffrench-Constant, 2017). While in MS and in other demyelinating diseases, remyelination occurs efficiently in young adults, with aging OPCs’ differentiation and maturation into oligodendrocytes declines, becoming a limiting factor for spontaneous remyelination (Sim, Zhao, Penderis, & Franklin, 2002).

Mesenchymal stem cells (MSCs) are undifferentiated multipotent stromal cells able to generate osteoblasts, adipocytes as well as chondrocytes, and capable of modulating the microenvironment through paracrine signals (Minguell, Erices, & Conget, 2001). Therefore, MSCs are viewed as cells with many potential clinical applications, in particular as autologous cell therapies (for review see Ding, Shyu, & Lin [2011]). In the context of MS, MSCs have several potential benefits. They are immunomodulatory and can therefore be used to reduce the tissue damage resulting from acute inflammatory episodes that are typical for the early stages of the disease. Indeed, transplanted MSCs are immunomodulatory and neuroprotective promoting functional recovery in MS animal models (Bai et al., 2009, 2012) and apparently elicit beneficial effects in human MS patients (Connick et al., 2012).

MSCs’ potential role in myelin regeneration is still being explored. While MSCs do not directly transdifferentiate to myelin-producing cells (Hunt et al., 2008), there is accumulating evidence suggesting that MSCs might beneficially influence remyelination by modulating endogenous progenitor activities. We have previously demonstrated that soluble factors derived from MSCs induce an oligodendrocyte fate on neural stem cells (NSCs; Rivera et al., 2006; Steffenhagen et al., 2012) and enhance OPC differentiation (Jadasz et al., 2013). Furthermore, cotransplantation of NSCs together with MSCs onto organotypic hippocampal slice cultures promoted oligodendrocyte differentiation of the transplanted NSCs (Rivera et al., 2009). Also, MSCs grafted into the fimbria of cuprizone-induced demyelinated mice significantly activated OPCs and supported remyelination (Jaramillo-Merchan et al., 2013). This capacity of MSCs to promote oligodendrogenesis is not restricted to rodents as soluble factors derived from human MSCs induce oligodendrocyte differentiation in human induced pluripotent stem cell-derived NSCs (Jadasz et al., 2018). In summary, MSC transplantation might be developed into a potentially powerful MS therapy (Connick et al., 2012; Freedman et al., 2010; Jadasz, Aigner, Rivera, & Kury, 2012). Here we ask whether MSCs retain their capacity to enhance the generation of new oligodendrocytes with aging.
2 | MATERIALS AND METHODS

2.1 | Animal subjects

Two-month-old and 17–20 months old male and female Fischer 344 rats (Charles River Deutschland GmbH, Germany) were used as young and old donors, respectively, for MSC cultures. Demyelinating surgeries were performed in 12-month-old male Fisher 344 rats (Harlan, UK) according to Home Office regulations. P0–P2 Sprague-Dawley rats (Internal Breeding Stock, University of Cambridge) were used for OPC cultures. Animal experiments within this research have been regulated under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB) in accordance with UK Home Office regulations (Project License: 70/7715).

2.2 | MSC cultures

MSC cultures from young and old rats were performed as previously described (Rivera et al., 2008). Briefly, bone marrow (BM) plugs were harvested from femurs and tibias of young (y; 2-month-old) and old (o; 17–20-month-old) male and female Fisher-344 rats (Charles River Deutschland GmbH, Germany). Plugs were mechanically dissociated in αMEM (Gibco Invitrogen, Karlsruhe, Germany) and recovered by centrifugation. Cell pellets were resuspended in αMEM containing 10% FBS (PAA, Austria) and 1% Penicillin/Streptomycin (PAN Biotech GmbH, Aiden Bach, Germany) (αMEM-10% FBS) and seeded at 1 x 10⁶ cells/cm². After 3 days, medium was changed, and nonadherent cells were removed. Adherent cells were incubated in fresh αMEM-10% FBS until a confluent layer of cells was achieved. Cells were trypsinized using 0.25% Trypsin (Gibco Invitrogen, Karlsruhe, Germany) and seeded in αMEM-10% FBS at 8,000 cells/cm². After 3–5 days of culture, the resulting monolayer of cells, hereafter named rat bone marrow-derived MSCs, was trypsinized and further cultured for experiments or frozen for later use. As demonstrated in our previous work, this cell culture preparation is highly enriched in multipotent MSCs with no more than 4.5% of hematopoietic contamination (Rivera et al., 2006). We named yMSCs when cells were isolated from young rats (2-month-old) and oMSCs (17–20-month-old) when isolated from old animals.

2.3 | NSC cultures

Tripotent NSCs derived from rat hippocampus were generated as described (Wachs et al., 2003). Briefly, hippocampi from 2-month-old male and female Fisher-344 rats (Charles River Deutschland GmbH, Germany) were aseptically removed and dissociated. Cells were resuspended in Neurobasal-A medium (NB-A; Gibco BRL, Germany) supplemented with B27 (Gibco BRL, Germany), 2 mM L-glutamine (PAN, Germany), 100 U/mL penicillin/0.1 mg/L streptomycin (PAN, Germany), hereafter referred to as NB/B27. For maintenance and expansion of the cultures, the NB/B27 was further supplemented with 2 mg/mL heparin (Sigma, Germany), 20 ng/mL FGF-2 (R&D Systems, Germany), and 20 ng/mL EGF (R&D Systems, Germany). As previously described (Rivera et al., 2006), immediately after plating of dissociated neurospheres in NB/B27-5% FBS, around 90% of the NSCs expressed the neural stem and progenitors markers such as nestin and A2B5. Cultures were maintained at 37°C in a humidified incubator with 5% CO₂. Neurosphere cultures from passage number 2–6 were used throughout this study and termed NSCs.

2.4 | OPCs cultures

OPCs were obtained from P0–P2 Sprague–Dawley rats (Internal Breeding Stock, University of Cambridge). Briefly, purified OPCs were obtained following the protocol of McCarthy and de Vellis. Cells from the cortex and hippocampus were dissociated and cultured in the presence of DMEM (Gibco, Carlsbad, CA) containing 1% P/S (Sigma Aldrich, Buchs, Switzerland) and 10% fetal bovine serum (FBS, Biosoer, Boussens, France) on poly-D-lysine coated flasks. After 10–12 days of mix glial cultures OPCs were mechanically dissociated from other glial cell types (McCarthy & de Vellis, 1980). OPCs were isolated by shaking off loosely adherent cells from the astrocyte adherent cell monolayer. The supernatant (enriched in OPCs) was collected and microglial cells were removed by incubation in plastic Corning petri dishes (BD, Oxford, UK) 15 min at 37°C. As previously described, this procedure results in a relatively pure population of OPCs (de la Fuente et al., 2015). Indeed, we determined that 92 ± 4% of total cells were Olig2-expressing undifferentiated OPCs. These cells are positive for the oligodendroglial lineage marker Olig2 and negative for the expression of mature oligodendrocyte markers, such as MBP and CNPase. OPCs were resuspended and plated in 13 mm poly-D-lysine (5 μg/mL) precoated coverslips (Thermo Scientific, Waltham, MA) in serum-free Sato media (DMEM supplemented with 0.3 mg/mL BSA fraction V [Sigma Aldrich], 0.1 mg/mL progesterone, 1.61 mg/mL putrescine, 25 μg/mL sodium selenite, 1% P/S 50 μg/mL of holo-Transferrin [Sigma Aldrich], and 5 μg/mL of insulin [Gibco]). OPCs were cultured in Sato media supplemented with 10 ng/mL of PDGF-AA and 10 ng/mL bFGF (Peprotech, Rocky Hill, NJ) to keep the cells in the proliferative stage.

2.5 | Organotypic cerebellar slices cultures

Demyelinating rat cerebellar slice cultures were prepared as previously described (Birgbauer, Rao, & Webb, 2004). Briefly, P9 rat cerebellum was isolated and 300 μm sections were obtained using Mcllwain tissue chopper (Mcllwain, San Antonio, TX). Slices were then incubated at 37°C with 5% CO₂ in organotypic slice medium (50% BME [Gibco], 25% heat-inactivated horse serum [Gibco], 25% HBSS [BME, Gibco], 5 mg/mL glucose, 1x glutamax [Gibco], and 1x Mycozap-PR plus [Lonza]). After a week in culture, slices were demyelinated with 0.5 mg/mL lyssolecithin for 16 hr and then incubated in lyssolecithin-free medium to allow remyelination.

2.6 | Growth curve and cell number determination

yMSCs and oMSCs from different passage number were plated at 5,000 cells per cm² and incubated in MSCs proliferation medium (αMEM-10%
FBS). The correct number of seeded cells was immediately confirmed using CASY-Cell Counter (Roche, Vienna Austria). Cells were incubated up to 1 week in αMEM-10% FBS. After 1, 3, 5, and 7 days incubation cells were detached with 0.25% Trypsin (Gibco BRL, Karlsruhe), collected in falcon tubes, centrifuged at 600g for 10 min and the cell pellet was resuspended in 1 mL αMEM-10% FBS. About 250 μL of each cell suspension was dissolved in CASYTON (Roche, Vienna Austria) and cell number was determined with CASY-Cell Counter (Roche, Vienna Austria). Measurements with CASY-Cell Counter were performed using the following settings: Dilution: 2.000e +00, Capillary: 150 μm, X-axis: 30 μm, sample volume: 400 μL cycles: 3, evaluation cursor: 9.00–30.00 μm, normal cursor 15–30.00 μm.

2.7 | MSC-conditioned media preparation

For experiments performed in NSCs, MSC-conditioned medium (MSC-CM) was prepared as described (Rivera et al., 2006). Briefly, yMSCs or oMSCs were plated at 12,000 cells/cm² and incubated in MSC proliferation medium (αMEM-10% FBS). For experiments performed in OPCs, yMSCs, or oMSCs were incubated with serum free Sato media (DMEM supplemented with 0.3 mg/mL BSA fraction V [Sigma Aldrich], 0.1 mg/mL progesterone, 1.61 mg/mL putrescine, 25 μg/mL sodium selenite, 1% P/S 50 μg/mL of holo-Transferrin [Sigma Aldrich], and 5 μg/mL of insulin [Gibco]) without PDGF-AA and bFGF. For experiments performed in demyelinated cerebellar slices, yMSCs, or oMSCs were incubated with organotypic slice culture medium (50% BME [Gibco], 25% heat inactivated horse serum [Gibco], 25% HBSS [BME, Gibco], 5 mg/mL glucose, 1x glutamax [Gibco] and 1x Mycozap-PR plus [Lonza]). Conditioned media was collected after 3 days in vitro and filtered through a 0.22 μm-pore filter.

2.8 | Bioluminescence assays

Bioluminescence assays were performed using noncommercial dual luciferase enzyme assay system. In this system, NSCs were cotransfected with (a) plasmid containing MBP promoter driving the expression of firefly luciferase (pMBP-Luci); (b) control vector that contains the cytomegalovirus (CMV) promoter driving the expression of Renilla luciferase (Promega, Mannheim, Germany). The two different luciferases use different specific substrates and therefore, the MBP regulatory region driven firefly luciferase activity was distinguished from Renilla luciferase. Transfected NSCs were seeded in Poly-L-Ornithine/Laminin-coated dishes in white-96-well plates and incubated either under control condition (αMEM-10% FBS) or in different MSC-CM dilutions. After 3 days NSCs were exposed to lysis solution that contained 25 mM Tris-phosphate pH 7.8, 2 mM DTT, 1% Triton X-100 (Sigma-Aldrich, Taufkirchen, Germany), 2 mM EDTA, 10% Glycerol (Merck, Darmstadt, Germany). To analyze the firefly luciferase activity cell lysate was treated with the following buffer: 25 mM glycylglycine (Acros, Geel, Belgium) 15 mM K2PO4 pH 8.0, 4 mM EGTA, 15 mM MgSO4 (Merck, Darmstadt, Germany), 2 mM ATP, 1 mM DTT, 0.1 mM Coenzyme A, 75 mM luciferin (Sigma-Aldrich, Taufkirchen, Germany). To analyze the Renilla luciferase activity cell lysate was treated with the following buffer: 1.1 M NaCl (VWR, Vienna, Austria), 2.2 mM Na2EDTA, 0.22 M K2PO4 pH 5.1 (Merck, Darmstadt, Germany), 0.44 mg/mL BSA (Biomol, Hamburg, Germany), 1.3 mM Na3 (Sigma-Aldrich, Taufkirchen, Germany), 1.43 mM coelenterazine (P.J.K., Kleinblittersdorf, Germany). Bioluminescence was measured by Luminometer (Tristar LB 941, Berthold Technologies, HVD, Austria) and luciferase activity was determined. In all conditions, firefly luciferase activity was normalized against the Renilla luciferase activity.

2.9 | NSCs, OPCs, and demyelinated cerebellar slices stimulation with yMSC-CM and oMSC-CM

NSCs were treated with yMSC-CM and oMSC-CM as previously described (Rivera et al., 2006). Briefly, NSCs were plated overnight onto poly-ornithine (250 μg/mL) and laminin (5 μg/mL)-coated glass coverslips at a density of 12,000 cells/cm² in αMEM-10% FBS. Next, media was replaced and cells were incubated either with yMSC-CM or oMSC-CM. NSCs were alternatively incubated in αMEM-10% FBS as control condition. Media was changed every third day of incubation. After 1 week of incubation, or alternatively after 3 days in the luciferase experiments, cells were fixed for 30 min with phosphate-buffered 4% paraformaldehyde (Sigma-Aldrich, Taufkirchen, Germany) and processed either for immunofluorescence, or for bioluminescence analysis, respectively.

OPCs were treated with yMSC-CM and oMSC-CM. OPCs were plated in 13 mm poly-α-lysine precoated coverslips (Thermo Scientific) at a density of 30,000 cells per cm². Cells were incubated for 3 days in Sato-based serum-free media supplemented daily with 10 ng/mL of PDGF-AA and 10 ng/mL bFGF to keep the cells in the proliferative stage. Next, media was switched to Sato-based yMSC-CM or oMSC-CM in the absence of growth factors. OPCs were alternatively incubated in Sato media without growth factors as a control condition. Media was replaced every 2 days and OPCs were fixed with phosphate-buffered 4% paraformaldehyde (pH 7.4) at 2 and 4 days of incubation and cells were processed for immunofluorescence.

After exposure to lysolecithin, demyelinated cerebellar slices were incubated with organotypic slice medium based yMSC-CM or oMSC-CM. Unconditioned organotypic slice medium was used as control. Treatment was replaced every other day and slices were collected at 2 and 6 days in vitro (DIV) post demyelination and fixed with 4% PFA for 1 hr. Then slices were stored in phosphate-buffered saline (PBS) 1× at −20°C for immunostaining.

2.10 | Immunocytochemistry and analysis

Fixed NSCs were washed in TBS (0.15 M NaCl, 0.1 M Tris—HCl, pH 7.5), then blocked with solution composed of TBS, 0.1% Triton-X100 (only for intracellular antigens), 1% bovine serum albumin (BSA), and 0.2% Tel- eostean gelatin (Sigma, Germany; fish gelatin buffer [FGB]). The same solution was used during the incubations with antibodies. Primary antibodies were applied overnight at 4°C. Fluorochrome-conjugated species-specific secondary antibodies were used for immunodetection. The following antibodies and final dilutions were used. Primary antibodies: rabbit anti-GFAP 1:1000 (Dako, Denmark), mouse anti-Myelin Basic Protein (MBP) 1:750 (SMI-94, Covance, Anopoli Biomedical
systems, Eichgraben, Austria, and rabbit. Secondary antibodies: donkey anti-mouse, rabbit conjugated with Alexa Fluor 488, Alexa 568 1:1000 (Molecular Probes, Eugene, OR). Nuclear counterstaining was performed with 4′,6-diamidino-2-phenylindole dihydrochloride hydrate at 0.25 μg/μl (DAPI; Sigma, Germany). Specimens were mounted on microscope slides using the Prolong Antifade kit (Molecular Probes). Epifluorescence observation and photo-documentation were realized using an Olympus IX81 microscope (Olympus, Germany) equipped with Hamamatsu digital camera and Volocity software (Perkin Elmer, Germany). For each culture condition, 5–10 randomly selected observation fields, containing in total 500–1,000 cells, were photographed for cell fate analysis. Expression frequency of selected cell type markers was determined for every condition in four independent experiments.

Fixed OPCs were washed in PBS before blocking. Next, cells were blocked with 5% normal donkey serum (Sigma, UK) and 0.1% Triton (Sigma, UK) in PBS for 1 hr at room temperature. The same solution was used during the incubation with antibodies. Primary antibodies were applied overnight at 4°C (rat anti-Myelin Basic Protein (MBP) 1:500 (Serotec), mouse anti-CNpase 1:400 (Abcam, UK) and goat anti-Olig2 1:200 (Abcam, UK). After three washes with PBS fluorochrome-conjugated species-specific secondary antibodies (488 anti-Goat 1:300 and Alexa fluor 568 anti-rat 1:500 or Alexa Fluor 647 anti-mouse 1:500 (Life Technologies, UK) were used for 2 hr at room temperature to detect primary antibodies. Nuclear counterstaining was performed with Hoechst 2 μg/mL (Sigma Aldrich). Epifluorescence observation and photo-documentation were realized using an Olympus IX81 microscope (Olympus, Germany) equipped with Hamamatsu digital camera and Volocity software (Perkin Elmer, Germany). Percentage of cells expressing Olig2 that also expressed the other mature OPC markers was determined in at least three independent experiments.

2.11 | Focal demyelination lesions
Male Fischer 344 rats aged 12 months were used to induce bilateral focal demyelination in the caudal cerebellar peduncle (CCP) in compliance with UK Home Office regulations (Project License: 70/7715, formerly 80/2228). Animals were anesthetized using a combination of 2% isoflurane in oxygen (as carrier gas) and a subcutaneous injection of buprenorphine hydrochloride 0.03 mg/kg (Vetregesic, Animalcare Ltd, Hull, UK). The procedure consisted on bilateral stereotactical injections of 4 μL of 0.01% ethidium bromide (v/v) into the CCP, −11.6 mm caudal, ±2.9 mm lateral, and −8.3 mm ventral from bregma (Woodruff & Franklin, 1999).

2.12 | MSCs stable transfection with mCherry
PiggyBac transposon-based strategy was used for MSCs stable transfection with mCherry (Yusa, Zhou, Li, Bradley, & Craig, 2011). The coding region of mCherry was amplified by PCR and cloned into the XbaI/EcoRI sites of the backbone PiggyBac vector PB-CMV-MCS-EF1-Puro (System Biosciences; Cat. No. PB5105B-1). For further genomic integration, the following vector was used: pCMV-hyPBase (provided by the Wellcome Trust Sanger Institute). MSCs obtained from 2 and 20 months old male rats were transfected with PB-CMV-mCherry-EF1-Puro and pCMV-hyPBase plasmids. Amaxa® Basic Nucleofector® Kit for Primary Mammalian Smooth Muscle Cells (Lonza) and the program U-023 were used to transfect 5 × 10^6 cells with 4 μg of PB-CMV-mCherry-EF1-Puro and 1 μg of pCMV-hyPBase. This methodology allowed approximately 40% of transfection efficiency. For further selection, transfected cells were incubated in the presence of 2 μg/mL puromycin (Sigma) for at least 1 week, leading to a highly pure mCherry-expressing MSCs culture.

2.13 | MSCs transplantation into demyelinated rats
mCherry-expressing MSCs were intravenously transplanted into rats after CCP demyelination. To reduce the probability of transplant rejection, we used male Fisher 344 (inbred strain) rats as MSCs donors and transplanted host. Previous to transplantation, cultured mCherry-expressing MSCs were collected in PBS at a suspension of 2 × 10^6 cells/ml with a survival rate of 80–98%. Three daily doses of 1.5–2.0 × 10^6 mCherry-expressing MSCs obtained from young and old donors were administrated through the tail vein of previously demyelinated rats at 1, 2, and 3 days post-lesion (dpl) induction. Tail vein infusion of PBS (1 mL) was used as vehicle control group. About 4–5 animals were considered per group. Animals were then perfused/fixed with 4% PFA at 21 dpl. Fixed brains were kept in 20% sucrose and embedded in optimal cutting temperature compound (Taab). Cryosections were obtained using a cryostat (Bright Instruments, Luton, Bedfordshire) at 12 μm thickness and then frozen at −80°C until further processing.

2.14 | Immunohistochemistry
Fixed cerebellar slices were washed in PBS and blocked for 1 hr with 10% NGS 0.5% Triton X-100 in agitation and incubated overnight with antibodies for MBP (1:500, Serotec, Kidlington, UK) and NFH (1:500, Abcam, Cambridge, UK) in blocking solution. Slices were washed three times with PBS and 0.1% Triton X-100. Slices were incubated with fluorochrome-conjugated secondary antibodies (AF488, AF568, 1:300, Invitrogen) for 2 hr at 20–26°C. The secondary antibodies were removed washing with PBS 0.1% Triton X-100 and then Hoechst (1 μg/mL, final concentration, Sigma) was used for nuclei staining. Slices were mounted with Fluoromount G onto poly-d-lysine slides, covered with a 20-mm coverslip (VWR, Radnor, PA) and prepared for confocal microscopy visualization and documentation.

Twelve micrometers sections were dried for 1 hr at RT and washed with PBS. Only for Olig2/APC stainings, antigen retrieval was performed by incubating the sections for 10 min at RT with preboiled 1x citrate buffer, pH 6.0 and antigen retriever (Dako). No antigen retrieval was performed for mCherry stainings. Then, slides were incubated for 2 hr at RT with blocking solution (5% normal donkey serum and 0.1% Triton X-100). After blocking, slices were incubated with primary antibodies overnight at 4°C, washed and incubated with secondary antibodies for 2 hr at RT in blocking solution. Nuclei were stained with 1 μg/mL Hoechst for 5 min, and slides were mounted after washes with Fluoromount G. Primary antibodies: rabbit anti-Olig2 antibodies (1:200;
R&D Systems), mouse anti-APC (1:200; EMD Millipore), rabbit anti-Ki67 (1:500; Abcam), mouse anti-Nkx2.2 (1:100; Developmental Studies Hybridoma Bank), goat anti-Iba1 (1:500; Abcam), rabbit anti-mannose receptor (MR) (1:200; Abcam), rabbit anti-Periaxin (1:1000; from Peter Brophy, Centre for Neuroscience Research, University of Edinburgh, UK), and rabbit anti-mCherry (1:200; Abcam). Fluorochrome-conjugated secondary antibodies: Donkey AF488 anti-rabbit (1:500; Invitrogen), Donkey AF488 anti-goat (1:500; Invitrogen), Donkey AF568 anti-rabbit (1:500; Invitrogen), and Donkey AF647 anti-mouse (1:500; Invitrogen).

**FIGURE 1** Legend on next page.
2.15 Histological analysis and quantification

For the quantification and analysis of slices derived from the ex vivo organotypic culture, four independent slices were analyzed per condition and per experiment. Five images of randomly chosen areas of each slice were imaged using Leica SP5 confocal microscope 40x objective (NA 1.25) with 1.5 digital zoom, 1,024 × 1,024 resolution and 1.75–2 μm thickness stacks. Slices derived from the same animal were counted as n = 1 and the different biological experiments were counted as independent experiments (individual n). For analysis, a macro was created in Image J, which measured the MBP-NFH colocalization area and the total NFH area.

For in vivo experiments, CCP lesions were recognized by the presence of increased cellularity denoted by Hoechst staining. For the quantification and analysis of the CCP lesion images, the whole lesion of three sections was imaged per animal with the 20x objective (NA 0.70), 1,024 × 1,024 resolution, and 1.5–2 μm stacks. This was performed for each CCP lesion (left and right) per animal. Using ImageJ software, the lesion area was delineated based on Hoechst channel as mentioned previously and measured. Then the number of different cell types OPCs (Olig2+/APC−), proliferating OPCs (Nkx2.2+/Ki67+), mature oligodendrocytes (Olig2+/APC+), and Schwann cells (Periaxin+) within the lesion was counted manually with the cell counter plugin. The number of macrophages/microglia cells (Iba1+ and MR+) was quantified using ImageJ software by applying the following constant parameters of brightness/contrast, threshold, particle size, and circularity, respectively: 0/255, 75/255, 20–350, 0–40 (for Iba1) and 0/185, 45/255, 60–350, 0.05–40 (for MR). All images were acquired at room temperature.

2.16 Oil red-O staining

Sections from control and treatment group were left to dry at room temperature and then placed in a Coplin jar containing propylene glycol (100%) for 5 min. Prewarmed Oil Red-O solution (0.5% in propylene glycol, Sigma-Aldrich) was stained at 65 °C for 10 min. Following incubation for 5 min with differentiation solution (85% propylene glycol), slides were rinsed twice with water and then mounted using a jelly-based mounting media. Representative images of Oil Red-O stained lesions were digitized, and, using ImageJ software, the intensity of the lesion area was measured from the red channel. Data are given as mean ± SEM and statistically analyzed. Three sections per marker per animal were analyzed, and a minimum of four animals were used.

2.17 Statistical analysis

Data are presented as means ± SD and statistical analysis was performed using PRISM4 (GraphPad, San Diego, CA) and SPSS (IBM, Headquarters). p values of <.05 were considered to be significant acquired by parametric one-way ANOVA and Tukey post hoc. For MSCs, growth curve and MSC-CM dose-dependent experiments, two-way ANOVA and Bonferroni post hoc were performed. For experiments carried out in organotypic slices, two-way ANOVA and Bonferroni post hoc were performed. For in vivo remyelination studies, 4–5 animals were considered per group and one-way ANOVA/Tukey post hoc were triplicated. If not mentioned otherwise, experiments were performed in triplicates.

3 RESULTS

3.1 Aging decreases the capacity of MSCs to promote the generation of oligodendrocytes in vitro

Soluble factors derived from yMSCs promote oligodendrocyte fate decision and differentiation at the expense of astrogenesis in tripotent NSCs (Rivera et al., 2006). To determine whether MSC aging affects their pro-oligodendrogenic activity, NSCs were incubated with conditioned media derived from yMSCs (yMSC-CM) as well as from oMSCs (oMSC-CM) and the oligodendrogenic effect was evaluated. NSCs under control conditions showed a typical flat and star-like astrocytic morphology (Figure 1a), while cells incubated in yMSC-CM and oMSC-CM displayed a multipolar oligodendroglial morphology with secondary branches (Figure 1e,i). Most NSCs incubated under control conditions differentiated into glial fibrillary acidic protein (GFAP)-expressing astrocytes (Figure 1b–d), whereas the majority of NSCs incubated in yMSC-CM as well as oMSC-CM give rise to myelin basic protein (MBP)-expressing...
oligodendrocytes (Figure 1f–h and j–l, respectively). Both yMSC-CM and oMSC-CM decreased the proportion of GFAP-expressing astrocytes compared to the control condition to a similar extent (Figure 1n). Thus, regardless of donor age, soluble factors derived from MSCs are able to induce an oligodendrocyte fate at the expense of astrogenesis. However, although both yMSC-CM and oMSC-CM increased the proportion of MBP-expressing oligodendrocytes compared to the control, yMSC-CM-induced a higher percentage of MBP-positive cells than oMSC-CM.

**FIGURE 2** Aged MSCs display a reduced ability to promote OPC differentiation. Neonatal OPCs were incubated in control serum free Sato media (a and e) and yMSC (b and f) and oMSC (c and g) conditioned serum-free Sato media for 2 and 4 days in vitro (DIV). Fluorescent images indicate the expression of differentiation CNP (red) and mature oligodendrocyte MBP (red) markers together with the pan oligodendrocyte lineage marker Olig2 (green). DAPI nuclear staining is shown in all fluorescent images. Quantitative analysis shows the percentage of CNP-Olig2 (i and j) or MBP-Olig2 (k and l) double-positive cells within the Olig2 expressing cells at 2 and 4 days of incubation. Scale bars = 50 μm. Note that both, yMSC-CM and oMSC increase OPC differentiation when compared to control. However, oMSC-CM displays a delayed and less effective activity in OPCs as is only evident at 4 days of incubation and not so pronounced when compared to yMSC-CM. Values are displayed as mean ± SD. Experiments were done in triplicate. Statistics were performed by one-way ANOVA and the Tukey post hoc test. *p < .05; **p < .01; ***p < .001.
NSCs (Figure 1m). Bioluminescence assays were used to confirm these findings. Although both yMSC-CM and oMSC-CM-induced an increase in MBP promoter activity compared to the control condition in a MSC-CM concentration-dependent manner (upon exposure to different MSC-CM dilutions), NSCs incubated with yMSC-CM displayed higher levels of luciferase activity compared to cells incubated in the presence of oMSC-CM (Figure 1o,p). Since long-term in vitro expansion alters the MSCs’ growth rate (Figure 1a,b) as well as inducing senescence in many cell types (Baxter et al., 2004), we evaluated whether MSC long term culture expansion might affect the oligodendrogenic capacity of MSCs. Thus, NSCs were exposed to conditioned medium obtained from MSCs of increasing passage number and MBP promoter activity was assessed by bioluminescence. Regardless of MSCs' donor age, long-term in vitro expansion did not influence the MSCs derived oligodendrogenic activity, as MSC-CM harvested from cells with high and low passage number similarly induced MBP promoter activity (Supporting Information Figure S1c, d). Overall, these results indicate that aging decreases the capability of MSCs to promote the generation of oligodendrocytes from NSCs.

As OPCs represent the major cellular source for remyelinating oligodendrocytes in the adult CNS (Zawadzka et al., 2010), we further asked whether young and old MSC were able to enhance OPC differentiation. Indeed, we have previously shown that MSCs-derived soluble factors enhance OPC differentiation (Jadasz et al., 2013). Thus, OPCs were incubated for 2 and 4 days in the presence of yMSC-CM or oMSC-CM and differentiation was evaluated (Figure 2a–h). Sato based OPC media without growth factors was used as a control condition. Overall, independent of MSC donor's age, soluble factors derived from MSCs increased the proportion of Olig2-expressing OPCs that differentiate into CNPase- and MBP-expressing oligodendrocytes when compared to control media (Figure 2i–l). However, the yMSC-CM pro-oligodendrogenic effect on OPCs was more efficient compared to exposure to oMSC-CM. When comparing with control media, 2 days of incubation with yMSC-CM was sufficient to initiate an increase in the generation of CNP- and MBP-expressing oligodendrocytes, while this effect was only evident after 4 days of exposure to oMSC-CM (Figure 2i–l). Moreover, the final proportion of CNP-expressing mature oligodendrocytes was higher when OPCs were incubated with yMSC-CM compared to oMSC-CM (Figure 2j).

yMSC-CM might also promote proliferation and/or survival in OPCs, thus, indirectly increasing the proportion of mature oligodendrocytes rather than directly inducing OPC differentiation. To assess this possibility, we determined whether MSC-CM influences the percentage of Ki67+ and Caspase3+ cells during OPC differentiation. No difference between yMSC-CM and control conditions was observed (Supporting Information Figure S2a,b), indicating that yMSC-CM enhances the generation of oligodendrocytes by promoting OPC differentiation rather than interfering with cell proliferation or survival. Due to the lack of effect of yMSC-CM on OPC proliferation and survival, it is very unlikely that MSC-CM obtained from old donors exert this effect. Therefore, oMSC-CM has a lower capacity to induce OPC differentiation compared to MSC-CM derived from young donors.

In summary, both young and aged MSCs can promote the generation of oligodendrocytes, although aged MSCs do so less successfully.
FIGURE 4  Only transplanted MSCs derived from young donors boost OPC differentiation during CNS remyelination. Twelve months old rats were demyelinated by ethidium bromide (EtBr) injection into the caudal cerebellar peduncle (a). One, two, and three days after demyelination, rats were systemically transplanted with yMSCs or oMSCs that express mCherry for their future detection (b). PBS is used as vehicle control. Fluorescent image shows the presence of mCherry-expressing MSCs in the demyelinated area at 21 days post-lesion (dpl) (c). Scale bar = 200 μm. Fluorescent images show the presence of OPCs (Olig2+/APC–) and the generation of new oligodendrocytes (Olig2+/APC+) in the lesion site of the different animal groups (d). Hoechst shows nuclei counterstaining. Dashed lines denote demyelinating lesion area (L). Scale bar = 100 μm. In merge images, the inset shows a magnification of the area delimited by the square. Quantitative analysis shows the number of all oligodendroglial lineage cells (Olig2+) OPCs, and differentiated oligodendrocytes within the demyelinated lesion area (mm²) of the distinct animal groups at 21 dpl (e). Note that only the animals that were transplanted with yMSCs display a higher number of differentiated oligodendrocytes (Olig2+/APC+) within the lesion site. Values are displayed as mean ± SD. Five animals were analyzed for the PBS group while four animals were analyzed for the group transplanted either with yMSCs or oMSCs. Statistics were performed by one-way ANOVA and the Tukey post hoc test. *p < .05; NS, not significant.
3.2 | Aging suppresses the ability of MSC-CM to enhance \textit{ex vivo} generation of myelin-like sheaths

Does the reduced oligodendrogenic activity of oMSCs have a further consequence on CNS regeneration? Remyelination is highly efficient in young individuals, but this efficiency declines with aging (Shields, Gilson, Blakemore, & Franklin, 1999; Sim et al., 2002). Therefore, we next asked whether MSC derived soluble factors could not only increase OPC differentiation but also enhance myelination and, if so whether aging might affect this activity. To address these questions we used a well-established \textit{ex vivo} myelination model, where organotypic cerebellar slice cultures are shortly exposed to lysolecithin to provoke demyelination (Birgbauer et al.,...

\textbf{FIGURE 5} Legend on next page.
3.3 | Aging interferes with the capacity of MSCs to enhance OPC differentiation during CNS remyelination in vivo

We further explored whether the age-related restriction in the ability of MSCs to promote the generation of oligodendrocytes and enhance remyelination is also observed in an in vivo context. We systemically transplanted, through the tail vein, 4.5–6.0 x 10^6 mCherry-expressing yMSCs or oMSCs in adult rats after bilateral demyelination of the caudal cerebellar peduncles (CCP) (Figure 4a,b; Woodruff & Franklin, 1999). PBS intravenous administration was used as a vehicle control. In this model, OPC differentiation occurs very efficiently in young animals, however, it is impaired with increasing age. Rats older than 12 months already display a reduced rate of OPC differentiation contributing to a significant delay in remyelination compared to young animals (<3 months; Shields et al., 1999; Sim et al., 2002). Therefore, middle age rats (12 months old) were used and sacrificed at 21 days post-lesion (dpl) to assess treatment efficiency.

We used mCherry labeling to evaluate whether systemically transplanted MSCs survive and reach the lesion area and, most likely, exert a paracrine impact on neighboring CNS-resident cells. Following the mCherry signal, we found that transplanted MSCs were able to reach the demyelinating lesion (Figure 4c). Regardless of the donor’s age, we found approximately 65 ± 25 mCherry-expressing MSCs per 1 mm^2 within the lesion area. Olig2 is expressed in all cells from the oligodendroglial lineage and we evaluated the expression of aminotransferase polyposis coli (APC) to distinguish between OPCs and differentiated oligodendrocytes. No difference was found among all groups in the total number of recruited Olig2+/APC− undifferentiated OPCs; however, only the animals that received yMSCs displayed a higher number of differentiated Olig2+ genes APC+ oligodendrocytes within the lesion site, while transplanted oMSCs exerted no significant effect on OPC differentiation (Figure 4d,e). During remyelination, activated and proliferating OPCs can be detected by the expression of the transcription factor Nkx2.2 and Ki67, respectively (Watanabe, Hadzic, & Nishiyama, 2004). Regardless of donor’s age, transplanted MSCs did not alter the number of Nkx2.2+/Ki67+ proliferating OPCs (Supporting Information Figure S3a,b). These findings together suggest that MSCs increased the number of new oligodendrocytes generated by boosting OPC differentiation instead of indirectly enhancing OPC proliferation. As expected, none of the mCherry positive cells were found to coexpress Olig2 (Supporting Information Figure S4), arguing against transdifferentiation of transplanted MSCs to oligodendrocytes.

During remyelination, OPC differentiation is favored by anti-inflammatory (M2) macrophages/microglia and inhibited by the presence of myelin debris (Miron et al., 2013). Therefore, we evaluated whether transplanted MSCs alter these particular properties that might indirectly influence OPC differentiation. Regardless of the donor’s age, transplanted MSCs neither affect the number of Iba1+ macrophages/microglia present within the demyelinated lesion nor their M2 polarization revealed by the appearance of mannose receptor (MR)-expressing subpopulation (Figure 5a,b). In addition, Oil Red O stainings, widely used to detect myelin debris in the lesion area (for example in Ruckl et al. [2012]), revealed no effect on the clearance of myelin debris after MSC treatments (Figure 5c,d). These data together with the previous in vitro findings suggest that transplanted MSCs directly exert their action on CNS-resident progenitor cells rather than modulating macrophages/microglia function and indirectly influencing OPCs differentiation.

Finally, as OPC derived Schwann cells can also contribute to remyelination in the CNS (Zawadzka et al., 2010), we evaluated whether transplanted MSCs influence this particular OPC feature. No changes were found in the number of Periaxin-positive cells, a well-established Schwann cell marker (Zawadzka et al., 2010), in response to...
FIGURE 6  Independently from donors age, transplanted MSCs do not alter the presence of Schwann cells during CNS remyelination. Twelve months old rats were demyelinated by ethidium bromide injection into the caudal cerebellar peduncle. One, two, and three days after demyelination, rats were systemically transplanted with mCherry-expressing yMSCs or oMSCs. PBS is used as vehicle control. Fluorescent images show the lesion site of the different animal groups at 21 dpl and the presence of Schwann cells (a). Scale bar = 100 μm. Hoechst shows nuclei counterstaining. Dashed lines denote demyelinating lesion area (L). Quantitative analysis shows the number of Periaxin-expressing cells present within the lesion area (b). Note that none of transplanted groups shows significant difference in the number of Schwann cells present within the lesion respect to vehicle group. Values are displayed as mean ± SD. Five animals were analyzed for the PBS group while four animals were analyzed for the group transplanted either with yMSCs or oMSCs. Statistics were performed by one-way ANOVA and the Tukey post hoc test. NS, not significant.
transplantation, indicating that MSCs do not alter OPC differentiation toward Schwann cells (Figure 6a,b). No cross-reaction between Periaxin and the inflammation marker Iba1 was observed (Supporting Information Figure S5), supporting the specificity of Periaxin to label Schwann cells. In summary, consistent with the previous in vitro and ex vivo findings, aging suppresses the capacity of transplanted MSCs to directly boost OPC differentiation and the further generation of new oligodendrocytes during in vivo remyelination.

4 | DISCUSSION

Aging affects homeostasis and reduces the regenerative capacity of various tissues and organs (Alt et al., 2012; Fulle et al., 2012; Ruckh et al., 2012). Besides systemic and local environmental cues, restrictions in the tissue-resident adult stem cells and their properties contribute to the age-related reduction in the regenerative potential. Here, we have shown that soluble factors derived from aged MSCs have a reduced ability to promote oligodendrogenesis in CNS stem and progenitor cells. It has been shown that aging influences the neurotrophic activity of MSCs (Brohlin, Kingham, Novikova, Novikov, & Wilberg, 2012), therefore it is likely that aged MSCs display a lower capacity to synthesize and/or release their yet unknown "oligodendrocyte differentiation factor(s)" when compared with MSCs derived from young donors. Despite the presence of an oligodendrogenetic activity, aged MSCs failed to boost OPC differentiation during remyelination. Moreover, while yMSC were able to enhance the generation of myelin-like sheaths in an ex vivo model, oMSC lacked this capacity, suggesting that even if oMSCs are able to promote OPC differentiation in vitro their effect may be limited during in vivo remyelination.

Aging decreases OPC differentiation and impairs endogenous CNS remyelination (Franklin & Ffrench-Constant, 2008; Shen et al., 2008; Shields et al., 1999; Sim et al., 2002). Nevertheless, in a previous study, it has been shown that remyelination efficiency in old animals can be restored after exposure to a youthful systemic milieu via heterochronic parabiosis (Ruckh et al., 2012) or treatment with molecules such as 9-cis retinoic acid (Huang et al., 2011). Together, these observations suggest that age-related myelin regeneration restrictions can be overcome by the contribution of a strong regenerative microenvironment or stimulus. Here, we observed an enhancement in OPC differentiation during remyelination in middle-aged CNS in response to systemic transplantation of MSCs obtained from young donors. Interestingly, even though only a few transplanted cells reach the lesion area, this pro-regenerative effect exerted by MSCs might be supported by this fact that enables a closer interaction with CNS-resident OPCs. These data suggest that transplanted MSCs might change the systemic and/or the CNS milieu exerting their oligodendrogenic activity and overcoming intrinsic age-related myelin repair limitations. However, similar to ex vivo myelination, aging abolishes this MSC pro-regenerative capacity as transplanted aged MSCs fail to boost OPC differentiation in the CNS of middle age recipients.

The age of 17–20 months for oMSCs was chosen for the following reasons: (a) 17–20 months reflects approximately a human age that ranges between 50 and 60 years, given the mean longevity of male Fischer 344 rats of 642 days (Chesky & Rockstein, 1976) and the mean life expectancy of the human male population of 69 years ("World Health Statistics 2016: Monitoring Health for the SDGs". World Health Organization); (b) life expectancy of MS patients is 10–15 years lower than that of the unaffected population (Compston & Coles, 2008), hence 55–60 years. Thus, we assume that 17–20 month old rats have a chronological/biological age of later stage MS patients, which are currently in the scope of MSC-MS trials.

Since MSCs display immunomodulatory and neuroprotective activities, systemic autologous MSC therapy has been proposed for the treatment of MS (Connick et al., 2012; Freedman et al., 2010). Here, we have shown for the first time that soluble factors derived from MSCs enhance ex vivo myelin-like sheath formation and that systemic MSCs transplantation boosts the generation of oligodendrocytes during CNS remyelination. Thus, this study strengthens the pro-regenerative activity of MSCs and provides a further rationale for autologous MSC transplantation in MS therapy. In addition, and as an alternative strategy, a continuous pharmacological supply of the MSC-derived oligodendrogenetic factor(s), which still need to be identified, could have a controlled and specific effect in the generation of new oligodendrocytes enhancing remyelination. However, this study argues on caution when developing this therapy for older MS patients as aging suppresses MSCs pro-oligodendrogenic activity. Thus, it clearly urges for a careful revision when designing clinical MSC-based trials for MS treatment. The use of young-donor derived MSCs, for example, umbilical cord-derived MSCs, might be more efficient than autologous MSCs from elderly patients.

ACKNOWLEDGMENTS

The authors would like to thank the following funding agencies for their support: Paracelsus Medical University PMU-FFF Long-Term Fellowship L-12/01/001-RIV and Stand-Alone Grant E-12/15/077-RIT [both to F.J.R.]; Chilean Comisión Nacional de Investigación Científica y Tecnológica [CONICYT] FONDECYT Program Regular Grant No. 1161787 [to F.J.R.], Regular Grant No. 1141015 [to L.F.B.]; Chilean CONICYT PDI Program Grant No. REDES170233 [to F.J.R.], Grant No. REDES180139 and Grant No. REDI170037; Chilean CONICYT FONDEF-IDEA Program Grant No. ID17AM0043 [to O.M.S. and F.J.R.]; European Union’s Seventh Framework Programme [FP7/2007-2013] under grant agreements No. HEALTH-F2-2011-278850 [INMiND] and HEALTH-F2-2011-279288 [IDEA]. The work in the Küry laboratory was supported by the German Research Foundation (DFG; KU1934/2-1, KU1934/5-1) and the Christiane and Claudia Hempel Foundation for clinical and iBrain. The work in the Franklin laboratory was supported by grants from the UK Multiple Sclerosis Society and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and a core support grant from the Wellcome Trust and MRC to the Wellcome-MRC Cambridge Stem Cell Institute. In addition, the present work was supported by the state of Salzburg (to L.A.). We thank Armin Schneider, Syngis Pharma AG Heidelberg, Germany, for the MBP promoter construct. We disclose any conflict of interest.
CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Francisco J. Rivera https://orcid.org/0000-0001-7895-6318
Alerie G. de la Fuente https://orcid.org/0000-0001-8366-4969
Chao Zhao https://orcid.org/0000-0003-1144-1621
Maria E. Silva https://orcid.org/0000-0001-6236-7180
Ginez A. Gonzalez https://orcid.org/0000-0002-2146-9655
Eleni Priglinger https://orcid.org/0000-0002-1484-0444
Pasquale Romanello https://orcid.org/0000-0003-0874-6918
Janusz J. Jadasz https://orcid.org/0000-0002-5505-4570
Andreas Traweger https://orcid.org/0000-0002-0220-4766
Luis F. Bátil https://orcid.org/0000-0002-3043-8797
Patrick Küry https://orcid.org/0000-0002-2654-1126
Sebastien Couillard-Despres https://orcid.org/0000-0002-8486-6412
Robin J. M. Franklin https://orcid.org/0000-0001-6522-2104
Ludwig Aigner https://orcid.org/0000-0002-1653-8046

REFERENCES

Alt, E. U., Senst, C., Murthy, S. N., Slakey, D. P., Dupin, C. L., Chaffin, A. E., ... Izadpanah, R. (2012). Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Research, 8(2), 215–225. https://doi.org/10.1016/j.scr.2011.11.002
Bai, L., Lennon, D. P., Caplan, A. I., DeChant, A., Hecker, J., Kranso, J., ... Miller, R. H. (2012). Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nature Neuroscience, 15(6), 862–870. https://doi.org/10.1038/nn.3109
Bai, L., Lennon, D. P., Eaton, V., Maier, K., Caplan, A. I., Miller, S. D., & Miller, R. H. (2009). Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia, 57(11), 1192–1203. https://doi.org/10.1002/glia.20841
Baxter, M. A., Wynn, R. F., Jovitt, S. N., Wraith, J. E., Fairbairn, L. J., & Bellantuono, I. (2004). Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells, 22(5), 675–682. https://doi.org/10.1634/stemcells.22-5-675
Birgbauer, E., Rao, T. S., & Webb, M. (2004). Lysoselecin induces demyelination in vitro in a cerebellar slice culture system. Journal of Neuroscience Research, 78(2), 157–166. https://doi.org/10.1002/jnr.20248
Brohlin, M., Kingham, P. J., Novikova, L. N., Novikov, L. N., & Wilberg, M. (2012). Aging effect on neurotrophic activity of human mesenchymal stem cells. PLoS One, 7(9), e45052. https://doi.org/10.1371/journal.pone.0045052
Chesky, J. A., & Rockstein, M. (1976). Life span characteristics in the male Fischer rat. Experimental Aging Research, 2(5), 399–407. https://doi.org/10.1080/03610737608257998
Compton, A., & Coles, A. (2008). Multiple sclerosis. Lancet, 372(9648), 1502–1517. https://doi.org/10.1016/S0140-6736(08)61620-7
Connick, P., Kolappan, M., Crawley, C., Webber, D. J., Patani, R., Michell, A. W., ... Chandran, S. (2012). Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurology, 11(2), 150–156. https://doi.org/10.1016/S1474-4422(11)70305-2
de la Fuente, A. G., Errea, O., van Wijngaarden, P., Gonzalez, G. A., Kemmink, C., Jarjour, A. A., ... Franklin, R. J. M. (2015). Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation. The Journal of Cell Biology, 211(5), 795–985. https://doi.org/10.1083/jcb.2015051119
Ding, D. C., Shyu, W. C., & Lin, S. Z. (2011). Mesenchymal stem cells. Cell Transplantation, 20(1), 5–14. https://doi.org/10.3727/096368910X562546
Franklin, R. J. M., & French-Constant, C. (2008). Remyelination in the CNS: From biology to therapy. Nature Reviews. Neuroscience, 9(11), 839–855. https://doi.org/10.1038/nrn2480
Franklin, R. J. M., & French-Constant, C. (2017). Regenerating CNS myelin—from mechanisms to experimental medicines. Nature Reviews. Neuroscience, 18(12), 753–769. https://doi.org/10.1038/nrn.2017.136
Freedman, M. S., Bar-Or, A., Atkins, H. L., Karussis, D., Frassoni, F., Lazarus, H., ... Uccelli, A. (2010). The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: Consensus report of the international MSCT study group. Multiple Sclerosis, 16(4), 503–510. https://doi.org/10.1177/1352458509359727
Fulle, S., Centurione, L., Mancinelli, R., Sancilio, S., Manzoli, F. A., & Di Pietro, R. (2012). Stem cell ageing and apoptosis. Current Pharmaceutical Design, 18(13), 1694–1717.
Huang, J. K., Jarjour, A. A., Nait Oumesmar, B., Kemmink, C., Williams, A., Krezel, W., ... Franklin, R. J. (2011). Retinoid X receptor gamma signaling accelerates CNS remyelination. Nature Neuroscience, 14(1), 45–53. https://doi.org/10.1038/nn.2702
Hunt, D. P., Irvine, K. A., Webber, D. J., Compston, D. A., Blakemore, W. F., & Chandran, S. (2008). Effects of direct transplantation of multipotent mesenchymal stromal/stem cells into the demyelinated spinal cord. Cell Transplantation, 17(7), 865–873.
Jadasz, J. J., Aigner, L., Rivera, F. J., & Kury, P. (2012). The remyelination Philosopher’s stone: Stem and progenitor cell therapies for multiple sclerosis. Cell and Tissue Research, 349(1), 331–347. https://doi.org/10.1007/s00441-012-1331-x
Jadasz, J. J., Kremer, D., Gottlie, P., Tzekova, N., Domke, J., Rivera, F. J., ... Kury, P. (2013). Mesenchymal stem cell conditioning promotes rat oligodendroglial cell maturation. PLoS One, 8(8), e71814. https://doi.org/10.1371/journal.pone.0071814
Jadasz, J. J., Tepe, L., Beyer, F., Samper Agrelo, I., Akkermann, R., Spitzhorn, L. S., ... Kury, P. (2018). Human mesenchymal stem factors induce hippocampal- and human neural stem cell dependent oligodendrogenesis. Glia, 66(11), 145–160. https://doi.org/10.1002/glia.23233
Jaramillo-Merchan, J., Jones, J., Ivorra, J. L., Pastor, D., Viso-Leon, M. C., Minguell, J. J., Erices, A., & Conget, P. (2001). Mesenchymal stem cells. Current Pharmaceutical Design, 7(1), 5–12. https://doi.org/10.2174/1381612013359727
Krezel, W., ... de la Fuente, A. G., Errea, O., van Wijngaarden, P., Gonzalez, G. A., Kemmink, C., Jarjour, A. A., ... Franklin, R. J. M. (2015). Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation. The Journal of Cell Biology, 211(5), 795–985. https://doi.org/10.1083/jcb.2015051119
Reich, D. S., Luccinetti, C. F., & Calabresi, P. A. (2018). Multiple Sclerosis. The New England Journal of Medicine, 378(2), 169–180. https://doi.org/10.1056/NEJMra1401483
Rivera, F. J., Couillard-Despres, S., Pedre, X., Ploetz, S., Caioni, M., Lois, C., ... Aigner, L. (2006). Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells. Stem Cells, 24(10), 2209–2219.

Rivera, F. J., Kandasamy, M., Couillard-Despres, S., Caioni, M., Sanchez, R., Huber, C., ... Aigner, L. (2008). Oligodendrogenesis of adult neural progenitors: Differential effects of ciliary neurotrophic factor and Mesenchymal stem cell derived factors. Journal of Neuroscience, 107, 832–843. https://doi.org/10.1111/j.1471-4159.2008.05674.x

Rivera, F. J., Siebzehnrubl, F. A., Kandasamy, M., Caioni, M., Poehler, A. M., ... Aigner, L. (2009). Mesenchymal stem cells promote oligodendroglial differentiation in hippocampal slice cultures. Cellular Physiology and Biochemistry, 24(3-4), 317–324. https://doi.org/10.1159/000233256

Ruckh, J. M., Zhao, J. W., Shadrach, J. L., van Wijngaarden, P., Rao, T. N., Wagers, A. J., & Franklin, R. J. (2012). Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell, 10(1), 96–103. https://doi.org/10.1016/j.stem.2011.11.019

Shen, S., Sandoval, J., Swiss, V. A., Li, J., Dupree, J., Franklin, R. J., & Casaccia-Bonnefil, P. (2008). Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nature Neuroscience, 11(9), 1024–1034. https://doi.org/10.1038/nn.2172

Shields, S. A., Gilson, J. M., Blakemore, W. F., & Franklin, R. J. (1999). Remyelination occurs as extensively but more slowly in old rats compared to young rats following glialtoxin-induced CNS demyelination. Glia, 28(1), 77–83.

Sim, F. J., Zhao, C., Penderis, J., & Franklin, R. J. (2002). The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. The Journal of Neuroscience, 22(7), 2451–2459.

Steffenhagen, C., Dechant, F. X., Oberbauer, E., Furtner, T., Weidner, N., Kury, P., ... Rivera, F. J. (2012). Mesenchymal stem cells prime proliferating adult neural progenitors toward an oligodendrocyte fate. Stem Cells and Development, 21(11), 1838–1851. https://doi.org/10.1089/scd.2011.0137

Wachs, F. P., Couillard-Despres, S., Engelhardt, M., Wilhelm, D., Ploetz, S., Vroemen, M., ... Aigner, L. (2003). High efficiency of clonal growth and expansion of adult neural stem cells. Laboratory Investigation, 83(7), 949–962.

Watanabe, M., Hadzic, T., & Nishiyama, A. (2004). Transient upregulation of Nkx2.2 expression in oligodendrocyte lineage cells during remyelination. Glia, 46(3), 311–322. https://doi.org/10.1002/glia.20006

Woodruff, R. H., & Franklin, R. J. (1999). Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lyssolecithin, ethidium bromide, and complement/anti-galactocerebroside: A comparative study. Glia, 25(3), 216–228.

Yusa, K., Zhou, L., Li, M. A., Bradley, A., & Craig, N. L. (2011). A hyperactive piggyBac transposase for mammalian applications. Proceedings of the National Academy of Sciences of the United States of America, 108(4), 1531–1536. https://doi.org/10.1073/pnas.1008322108

Zawadzka, M., Rivers, L. E., Fancy, S. P., Zhao, C., Tripathi, R., Jamen, F., ... Franklin, R. J. (2010). CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell, 6(6), 578–590. https://doi.org/10.1016/j.stem.2010.04.002

Zhang, H., Jarjour, A. A., Boyd, A., & Williams, A. (2011). Central nervous system remyelination in culture—A tool for multiple sclerosis research. Experimental Neurology, 230(1), 138–148. https://doi.org/10.1016/j.expneurol.2011.04.009

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Rivera FJ, de la Fuente AG, Zhao C, et al. Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination. Glia. 2019;67:1510–1525. https://doi.org/10.1002/glia.23624